Cenobamate: First Approval
Author:
- 13 January 2020
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 80 (1) , 73-78
Abstract
Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients. This article summarizes the milestones in the development of cenobamate leading to this first approval.Keywords
This publication has 8 references indexed in Scilit:
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trialThe Lancet Neurology, 2020
- Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)Neurology, 2019
- Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neuronsEuropean Journal of Pharmacology, 2019
- Effects of Cenobamate on GABA-A Receptor Modulation (P1.5-033)Neurology, 2019
- The Pharmacokinetics of Cenobamate in Special Populations (P1.5-034)Neurology, 2019
- Time to Onset of Efficacy in Seizure Reduction With Cenobamate (YKP3089) in Patients With Uncontrolled Partial Seizures From 2 Randomized Clinical Trials (P1.5-032)Neurology, 2019
- Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Multicenter, Open-Label Study (P1.5-019)Neurology, 2019
- Pharmacokinetics of Cenobamate (YKP3089): Results From Single and Multiple Oral Rising-Dose Studies in Healthy Subjects (P5.280)Neurology, 2018